Genmab A-S Aktie

188,45 EUR -1,15 EUR -0,61 %

08:10:55

STU

171,10 CHF -2,84 CHF -1,63 %

09:48:21

BRX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.11,78 Mrd. EUR

KGV12,21Div. Rendite0,00%

WKN565131

ISINDK0010272202

SymbolGNMSF

Genmab A-S Aktien News

Sortieren:Datum Meistgelesen

02.02.24GlobeNewswireTisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

30.01.24finanzen.netErste Schätzungen: Genmab A-S stellt Ergebnisse des abgelaufenen Quartals vor

30.01.24finanzen.netErste Schätzungen: Genmab A-S (spons ADRs) legt Zahlen zum jüngsten Quartal vor

25.01.24GlobeNewswireGrant of Restricted Stock Units and Warrants to Employees in Genmab

23.01.24GlobeNewswireGenmab Announces Net Sales of DARZALEX® (daratumumab) for 2023

23.01.24GlobeNewswireGenmab Announces Decision in Arbitration Appeal under License Agreement with Janssen

09.01.24GlobeNewswireTIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer

03.01.24GlobeNewswireTransactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

02.01.24GlobeNewswireGenmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference

12.12.23GlobeNewswireGenmab to Hold 2023 R&D Update and ASH Data Review Meeting

09.12.23GlobeNewswireNew Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)

09.12.23PR NewswireNew Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

05.12.23GlobeNewswireCapital Increase in Genmab as a Result of Employee Warrant Exercise

27.11.23GlobeNewswireGenmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

21.11.23GlobeNewswireTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

21.11.23GlobeNewswireGrant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

09.11.23GlobeNewswireMajor Shareholder Announcement

09.11.23GlobeNewswireGenmab to Present at Jefferies London Healthcare Conference

08.11.23GlobeNewswireMajor Shareholder Announcement

07.11.23GlobeNewswireGenmab Announces Financial Results for the First Nine Months of 2023

06.11.23finanzen.netAusblick: Genmab A-S legt Zahlen zum jüngsten Quartal vor

06.11.23finanzen.netAusblick: Genmab A-S (spons ADRs) gibt Ergebnis zum abgelaufenen Quartal bekannt

02.11.23GlobeNewswireGenmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)

23.10.23finanzen.netErste Schätzungen: Genmab A-S gibt Ergebnis zum abgelaufenen Quartal bekannt

23.10.23finanzen.netErste Schätzungen: Genmab A-S (spons ADRs) stellt Ergebnisse des abgelaufenen Quartals vor

22.10.23GlobeNewswireTIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

17.10.23GlobeNewswireGenmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023

28.09.23GlobeNewswireGrant of Restricted Stock Units and Warrants to Employees in Genmab

25.09.23GlobeNewswireGenmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

25.09.23GlobeNewswireEPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Ce

12.09.23GlobeNewswireCapital Increase in Genmab as a Result of Employee Warrant Exercise

04.09.23GlobeNewswireGenmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

28.08.23GlobeNewswireGenmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference

15.08.23GlobeNewswireCapital Increase in Genmab as a Result of Employee Warrant Exercise

04.08.23finanzen.netGenmab A-S zog Bilanz zum jüngsten Jahresviertel

04.08.23finanzen.netGenmab A-S (spons ADRs) öffnete die Bücher zum abgelaufenen Quartal

03.08.23GlobeNewswireGenmab Announces Financial Results for the First Half of 2023

02.08.23finanzen.netAusblick: Genmab A-S legt die Bilanz zum abgelaufenen Quartal vor

02.08.23finanzen.netAusblick: Genmab A-S (spons ADRs) legt Zahlen zum jüngsten Quartal vor

28.07.23GlobeNewswireGenmab Updates 2023 Financial Guidance

Genmab A-S News

Genmab A-S News: auf dieser Seite finden Sie alle Genmab A-S News und Nachrichten zur Genmab A-S Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Genmab A-S News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Genmab A-S News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.